Advances in the Management of Metastatic Breast Cancer with SABCS Updates

The decision-making process for management of mBC should involve careful consideration of the available evidence for selection of optimal therapy and a detailed discussion of the benefits and risks associated with all possible treatment strategies with patients. With expanding treatment options, clinicians should understand important criteria used in selecting optimal first-and subsequent-line therapies for individuals with mBC. This session focuses on the available treatment options and how to integrate new evidence-based data into clinical practice.

Target Audience

This program is designed to meet the educational needs of physicians, nurse practitioners, nurses, physician associates, pharmacists, social workers, and other health care professionals who treat patients with breast cancer. 

Learning Objectives

Following this activity, participants should be able to:

  • Utilize evidence-based approaches to select optimal first- and subsequent-line treatment options for patients with metastatic breast cancer.
  • Outline new and emerging therapeutic options for metastatic breast cancer.

Additional information
Supporters: 

This activity is supported by educational grants from:

  • AstraZeneca
  • Lilly
  • Menarini-Stemline
  • Novartis
  • Puma Biotechnology

This activity is supported through independent medical education grants from: 

  • Daiichi Sankyo
  • Merck & Co., Inc., Rahway, NJ, USA.

Supported by a grant from Pfizer Inc.

Course summary
Available credit: 
  • 1.25 AAPA Category 1 CME credit
  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 ASWB continuing education credit
  • 1.25 Participation
Course opens: 
03/15/2026
Course expires: 
03/14/2027
Part of: 
Recorded Presentations from the NCCN 2026 Breast Cancer Congress with Updates from the 2025 San Antonio Breast Cancer Symposium

William J. Gradishar, MD, Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Frederick M. Howard, MD, The UChicago Medicine Comprehensive Cancer Center
Melinda L. Telli, MD, Stanford Cancer Institute
 

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures
The faculty listed below have the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated. 
 

William J. Gradishar, MD 
AstraZeneca Pharmaceuticals LP: Honoraria; Scientific Advisor
Carrick Therapeutics, Inc.: Scientific Advisor
Daiichi-Sankyo Co.: Honoraria; Scientific Advisor
Eli Lilly and Company: Scientific Advisor
Stemline Therapeutics, Inc.: Scientific Advisor

Frederick M. Howard, MD
Leica Biosystems: Consulting Fee
Novartis Pharmaceuticals Corporation: Consulting Fee

Melinda L. Telli, MD
Arvinas: Grant/Research Support; Scientific Advisor
AstraZeneca Pharmaceuticals LP: Scientific Advisor
BioNTech: Grant/Research Support; Scientific Advisor
Blueprint Medicines: Scientific Advisor
Celcuity: Consulting Fee
Foresight Diagnostics: Scientific Advisor
G1 Therapeutics: Consulting Fee
Genentech, Inc.: Grant/Research Support; Scientific Advisor
Gilead Sciences, Inc.: Consulting Fee; Scientific Advisor
Lilly: Scientific Advisor
Merck & Co., Inc.: Grant/Research Support; Scientific Advisor
Natera: Scientific Advisor
Novartis Pharmaceuticals Corporation: Scientific Advisor
OncoSec Medical: Grant/Research Support; Scientific Advisor
Pfizer Inc.: Grant/Research Support; Scientific Advisor
sanofi-aventis U.S.: Scientific Advisor
Summit Therapeutics: Scientific Advisor

NCCN Staff Disclosures
None of the other planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
 
image
Joint Accreditation
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians
NCCN designates this enduring material for 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for 1.25 contact hours.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.25 contact hours (0.125 CEUs) of continuing education credit. UAN: JA4008196-0000-26-025-H01-P

Physician Associates
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. Approval is valid until March 14, 2027. PAs should only claim credit commensurate with the extent of their participation.

Social Workers
As a Jointly Accredited Organization, NCCN is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. NCCN maintains responsibility for this course. Social workers completing this course receive 1.25 continuing education credits.

American Board of Internal Medicine Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1.25 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregated participant data will be shared with the commercial supporters of this activity.
American Board of Pathology Continuing Certification (CC)
This activity has been registered to offer credit in the American Board of Pathology’s (ABPath) Continuing Certification program. Successful completion of this CME activity enables the participant to earn 1.25 Lifelong Learning (Part II) credits. Aggregated participant data will be shared with the commercial supporters of this activity.
American Board of Surgery Continuous Certification (CC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME requirements of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

American Board of Medical Specialties (MOC)
Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Continuing Certification Activities through the ABMS Continuing Certification Directory, the NCCN 2026 Breast Cancer Congress with Updates from the 2025 San Antonio Breast Cancer Symposium has met the requirements as a Lifelong Learning CME Activity (apply toward general CME requirement) by the following ABMS Member Boards:

MOC Part II CME Activity
Medical Genetics and Genomics 
Radiology

Permission to Upload Credits
For ABIM, ABPath, and ABS MOC points, your information will be shared with your board through NCCN's Joint Accreditation Program and Activity Reporting System (JA-PARS). Please allow 6-8 weeks for your MOC points to appear on your board records.

By sharing your Diplomate Board ID # and DOB, you are giving NCCN permission to use this information/data to report your participation to these boards via JA-PARS.

Available Credit

  • 1.25 AAPA Category 1 CME credit
  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 ASWB continuing education credit
  • 1.25 Participation
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing